| 2005 Symposium Presentations |
| |
To view video and slides of these presentations, click on presentation title. This will open a new browser window in which the audio, video, and slides for that presentation will be shown. If you have problems viewing the presentations via the Internet, we are offering a DVD version of the conference presentations for viewing on computers running Windows XP. At this time the DVD is free. To order, please e-mail eppinger@cmu.edu.
|
| |
| Monday, October 24, 2005 |
| |
| Plenary Session |
Welcome and Introduction
Francesmary Modugno, PhD, MPH • University of Pittsburgh
Ronald B. Herberman, MD • University of Pittsburgh
|
Opening Keynote: Genetic Analysis of Ovarian Cancer Histogenesis
Jeff Boyd, PhD, MPH • Memorial Sloan-Kettering Cancer Center
|
| |
| Epidemiology of Ovarian Cancer |
Molecular Studies of Ovarian Cancer in a Multiethnic Population
Marc T. Goodman, PhD, MPH • University of Hawaii
|
Screening for Ovarian Cancer in High Risk Women
Patricia Hartge, ScD • National Cancer Institute
|
New Directions in Ovarian Cancer Epidemiology and Prevention
Joellen Schildkraut, PhD • Duke University
|
Panel Discussion
Roberta B. Ness, MD, MPH • University of Pittsburgh
|
| |
| From Epidemiology to Ovarian Cancer Biology |
Pregnancy and Ovarian Cancer: Role of Endogenous Hormones
Paolo Toniolo, MD, MSPH • New York University
|
Modeling Epithelial Ovarian Cancer in the Mouse
Denise Connolly, PhD • Fox Chase Cancer Center
|
Mechanism of Ovarian Cancer Predisposition in Individuals with Germline BRCA1 Mutation
Louis Dubeau, MD, PhD • University of Southern California
|
Panel Discussion
Emanuela Taioli, MD, PhD • University of Pittsburgh
|
| |
| Screening and Early Detection - Emerging Technologies |
A Proteomics Approach to the Detection of Ovarian Cancer
Eric Fung, MD, PhD • Ciphergen Diagnostics
(Video and slides cannot be made available for this presentation)
|
Application of Proteomics Technologies to Advance our Understanding of Ovarian Cancer
Elise Kohn, MD • National Cancer Institute
(Video and slides cannot be made available for this presentation)
|
Can We Detect Early Stage Epithelial Ovarian Carcinoma?
David Fishman, MD • New York University
|
Multiplexed Serum Assay for Early Detection of Ovarian Cancer
Anna Lokshin, PhD • University of Pittsburgh
|
Panel Discussion
Joel Weissfeld, MD, MPH • University of Pittsburgh
|
| |
| Genetic and Epigenetics |
An Update on the HapMap
Wendy Wang, PhD • National Cancer Institute
(Video and slides cannot be made available for this presentation)
|
Prevention and Early Detection in Women at Increased Genetic Risk
Mark H. Greene, MD • National Cancer Institute
|
Variable Expression and Activity of Pharmacokinetic Variables in Ovarian Tumors
Julie A. DeLoia, PhD • University of Pittsburgh
|
Panel Discussion
Francesmary Modugno, PhD, MPH • University of Pittsburgh
|
| |
| Survivor and Advocate Educational Session |
Survivor and Advocacy Groups: A Role in Research, Education, and Beyond
Julene Fabrizio, President • National Ovarian Cancer Coalition
Patricia Goldman, President Emeritus • Ovarian Cancer National Alliance
|
Complementary and Alternative Therapies for Ovarian Cancer Patients: Overview
Maria B. Yaramus, PharmD • University of Pittsburgh
|
Magee-Womens Hospital Holistic Center Ovarian Cancer Support Group
Karen Cooper, LCSW • Magee-Womens Hospital of UPMC
|
T'ai Chi, Chi Kung, and Supportive Care
David Clippinger, PhD • Still Mountain T'ai Chi and Chi Kung
|
Restorative Yoga and Supportive Care
Leta Koontz • Schoolhouse Yoga
|
Meditation and Guided Imagery: Pathways to Spiritual Health and Well-Being
Brenda Cole, PhD • University of Pittsburgh
|
Healthy Choices and Healthy Snacking
Rita Beaver, RD • Magee-Womens Hospital of UPMC
Chris Fennimore • WQED Multimedia
|
Acupuncture and Symptom Distress
Ronald Glick, MD • University of Pittsburgh
|
Methods of Diagnosis using Acupuncture
Jim Poepperling L.Ac. SDPT, MTOM • University of Pittsburgh Medical Center
|
| |
| Reception and Mini-Symposium |
|
Abstracts
|
Tissue Microarray Analysis of Biomarkers p53, BRCA1, Annexin I, and Gelsolin Supports the Two-Pathway Theory of Ovarian Serous Carcinoma
Peggy Soung, MD • University of California at Los Angeles
|
United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Design and Characteristics of the Study Population
Usha Menon, MD, MRCOG, MBBS • University College London
|
1H-NMR-Based Metabonomics for the Detection of Epithelial Ovarian Cancer
Kunle Odunsi, MD, PhD • Roswell Park Cancer Institute
|
Identifying Associations between SNPs in Cell Cycle Control Genes and Susceptibility to Ovarian Cancer
Simon Gayther • University College London
|
Gene expression profiling of ovarian tumors obtained prior to and after chemotherapy: identification of putative marks implicated in mechanisms of chemoresistance
Sylvain L'Esperance • Centre de recherche de l'Hôtel-Dieu de Québec
(Video and slides cannot be made available for this presentation)
|
A Role for Micro Tubule-Associated Serine Protease HtrA1 in Chemotherapy-induced Cytotoxcity
Jeremy Chein, PhD • Mayo Clinic College of Medicine
|
| |
| Tuesday, October 25, 2005 |
| |
| Plenary Session |
Plenary Keynote: The Challenges of Reducing Overian Cancer Mortality
Karen Johnson, MD, PhD, MPH • Branch Chief, Breast and Gynecologic Malignancies, National Cancer Institute
|
| |
| Beyond Treating the Patient - Survivorship Issues |
Advocacy, Patient Care, and the Research Community
Julene Fabrizio, President • Ovarian Cancer National Alliance
|
Beyond Treating the Patient
Patricia Goldman, President Emeritus • Ovarian Cancer National Alliance
|
Ovarian Cancer: Insider Perspectives
Barbara Smith • National Ovarian Cancer Coalition
Cynthia DePastino • National Ovarian Cancer Coalition
|
Psycho-Social Issues in Diagnosis and Recurrence: Effects on Patients and their Families
Heidi Donovan, PhD • University of Pittsburgh
|
Integrating Complementary Medicine with Conventional Treatment
Ronald Glick, MD • University of Pittsburgh Medical Center
|
| |
| New Directions in Therapeutics and Prevention I |
Peritoneal Immunotherapy
Ralph S. Freedman, MD, PhD • University of Texas
|
Vaccines Targeting Ovarian Cancer
Mary L. (Nora) Disis, MD • University of Washington
|
Immunobiology of MUC1 Tumor Antigen: Lessons Learned and Future Implications in Ovarian Cancer
Anda Vlad, MD, PhD • University of Pittsburgh
|
Evolution of NY-ESO-1 Vaccine Therapy for Ovarian Cancer
Kunle Odunsi, MD, PhD • Roswell Park Cancer Institute
|
Panel Discussion
Kristin Zorn, MD • Magee-Womens Hospital of UPMC
|
| |
| New Directions in Therapeutics and Prevention II |
TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemo-Resistance in Ovarian Cancer
Thomas Rutherford, MD, PhD • Yale University
|
Oregovomab: Challenges, Lessons, and Opportunities
Christopher Nicodemus, MD • Unither Pharmaceuticals, Inc
|
Novel Approaches for Platinum Refractive Cancer
Robert P. Edwards, MD • Magee-Womens Hospital of UPMC
|
Individualizing Cancer Therapy: Current Status, Future Directions
Holly Gallion, MD • Precision Therapeutics, In
|
Panel Discussion
Thomas Krivak, MD • Magee-Womens Hospital of UPMC
|